Moses Darpolor1, Peter Kennealey2,
H. Carl Le1, Kristen Zakian1, Ellen Ackerstaff1,
Asif Rizwan1, Jin-Hong Chen2, Eliot Sambol2,
1Medical Physics, MSKCC,
Combined irinotecan and flavopiridol therapy is in clinical trials to treat human colon malignancies. Using in vivo and in vitro MR measurements we report here several critical HCT-116 cellular markers from the treatment. We have shown that flavopiridol is effective in inhibiting choline kinase by lowering phosphocholine/choline levels in vitro, while 31P MRSI detected an in vivo transient decrease in phosophocholine level following the treatment with both drugs. Detectable cholesterol/CH3 levels were observed to increase in tandem with HCT-116 cancer cell apoptotic fraction.